Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. The BPI-572270 capsules declared by the company's wholly-owned subsidiary Hangzhou Jingyao Biotechnology Co., Ltd. (hereinafter referred to as “Jingyao Biotech”) for phase I/II clinical studies on advanced solid tumor patients with specific RAS mutations have been reviewed and approved by the Australian Human Research Ethics Committee (“HREC”) and completed the Australian Drug Administration (“TGA” for short) ) Clinical trial registration. This is the company's first new drug approved for clinical trials in Australia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.